HB 4110
Allows an attending physician to provide ibogaine to a patient for the patient's consumption to treat certain disorders.
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take actionPublic sentiment
Support
78%
Oppose
22%
- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Bill overview
This bill allows an attending physician to provide ibogaine to a patient for treatment, defining key terms like "attending physician" and "ibogaine." It exempts ibogaine from being classified as a controlled substance when obtained, provided, and consumed as specified. The law also requires ibogaine administration in a controlled setting with on-site cardiac monitoring and takes effect 91 days after the legislative session ends.
Sponsors
Official sponsors from legislative records.
Primary sponsors
Cosponsors
Arguments in favor
Reasons to support this legislation.
Supporters of the legislation advocate for expanded access to alternative treatment options, particularly for rural areas struggling with mental health services. They cite positive public health benefits from regulated markets and trial studies on ibogaine, such as Oregon's psilocybin services, which have shown promise in addressing various disorders. Proponents emphasize the importance of administering ibogaine in controlled environments under medical supervision to mitigate risks, citing successes in Mexico and prioritizing patient safety while allowing innovation in treatment approaches. By supporting HB 4110, they aim to provide more options for individuals struggling with conditions such as PTSD and TBI, and to facilitate further research on the efficacy of ibogaine as a treatment option.
Source: Testimony Summaries
Arguments opposed
Reasons to oppose this legislation.
Representatives from various medical organizations in Oregon express strong opposition to House Bill 4110, citing concerns about the potential risks associated with ibogaine treatment. They argue that the bill's provisions could lead to physicians losing their DEA registration, despite ibogaine being a federally illicit substance, posing significant risks to patient safety and public health. Additionally, these organizations emphasize the need for evidence-based medical standards, highlighting the lack of rigorous scientific research supporting the use of ibogaine as a treatment option. By prioritizing caution and adherence to established medical protocols, opponents of HB 4110 seek to protect both patients and the medical community from potential harm.
Read the latest version inline or switch to a previous version.